Revisiting choline alphoscerate profile: a new, perspective, role in dementia?

Abstract

Choline alphoscerate (alpha-glyceryl-phosphorylcholine, alpha-GPC) is a semisynthetic derivative of phosphatidylcholine with central parasympathomimetic action. This action is, on the basis of its use in pathologies, characterized by cognitive deficits of neurodegenerative or vascular nature. In a number of clinical studies, alpha-GPC demonstrated benefit in patients with cognitive dysfunction. In light of the limited therapeutical results obtained in the past decades by the use of cholinesterase inhibitors in dementia, and of the relevance of their side effects in long-lasting therapies, it is desirable to reconsider alpha-GPC in larger carefully controlled studies not only as monotherapy but also in association with cholinesterase inhibitor drugs.

• Authors: Pier Luigi Scapicchio
• Journal: The International journal of neuroscience (Int J Neurosci) Vol. 123 Issue 7 Pg. 444-9 (Jul 2013) ISSN: 1563-5279 [Electronic] England
• PMID: 23387341 (Publication Type: Journal Article, Review)

Chemical References

• Nootropic Agents
• Glycerylphosphorylcholine

Topics

• Animals
• Cognition Disorders (drug therapy)
• Dementia (drug therapy)
• Glycerylphosphorylcholine (therapeutic use)
• Humans
• Nootropic Agents (therapeutic use)